Advanced search
Publication Cover
Nanomedicine Volume 9, 2014 - Issue 7
Submit an article Journal homepage
306
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Active Targeting of Mesoporous Silica Drug Carriers Enhances γ-Secretase Inhibitor Efficacy in An In Vivo Model for Breast Cancer

Rainer Wittig1 Institute for Laser Technologies in Medicine & Metrology at Ulm University, Helmholtzstrasse 12, D-89081 Ulm, GermanyView further author information
,
Jessica M Rosenholm2 Center for Functional Materials, Laboratory for Physical Chemistry, Department of Natural Sciences, Åbo Akademi University, FI-20500 Turku, FinlandView further author information
,
Eva von Haartman2 Center for Functional Materials, Laboratory for Physical Chemistry, Department of Natural Sciences, Åbo Akademi University, FI-20500 Turku, FinlandView further author information
,
Jarl Hemming3 Wood & Paper Chemistry, Department of Chemical Engineering, Åbo Akademi University, FI-20500 Turku, FinlandView further author information
,
Felicitas Genze4 Institute of Pharmacology of Natural Products & Clinical Pharmacology, Ulm University, Helmholtzstrasse 20, D-89081 Ulm, GermanyView further author information
,
Lotta Bergman5 Inorganic Chemistry II, Ulm University, Albert-Einstein-Allee 11, D-89081 Ulm, GermanyView further author information
,
Thomas Simmet4 Institute of Pharmacology of Natural Products & Clinical Pharmacology, Ulm University, Helmholtzstrasse 20, D-89081 Ulm, GermanyView further author information
,
Mika Lindén6 Turku Centre for Biotechnology, University of Turku & Åbo Akademi University, P.O. Box 123, FI-20521 Turku, FinlandView further author information
&
Cecilia Sahlgren8 Department of Biomedical Engineering, Technical University of Eindhoven, 2612Eindhoven, The Netherlands;7 Department of Biosciences, Cell biology, Åbo Akademi University, FI-20520 Turku, FinlandCorrespondence[email protected]
View further author information
 show all
Pages 971-987 | Received 12 Nov 2012, Published online: 30 Jun 2014

References

  • Hearty S , LeonardP, O‘KennedyR. Nanomedicine: barcodes check out prostate cancer. Nat. Nanotechnol.5(1), 9–10 (2010).
  • Ranganathan R , MadanmohanS, KesavanAet al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int. J. Nanomed. 7, 1043–1060 (2012).
  • Schroeder A , HellerDA, WinslowMMet al. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 12(1), 39–50 (2012).
  • Vinogradov S , WeiX. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomed. (Lond.)7(4), 597–615 (2012).
  • Waite CL , RothCM. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit. Rev. Biomed. Eng.40(1), 21–41 (2012).
  • Wang J , LuZ, GaoY, WientjesMG, AuJL. Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomed. (Lond.)6(9), 1605–1620 (2011).
  • Peer D , KarpJM, HongS, FarokhzadOC, MargalitR, LangerR. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2(12), 751–760 (2007).
  • Gary-Bobo M , HocineO, BrevetDet al. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. Int. J. Pharm. 423(2), 509–515 (2012).
  • Gary-Bobo M , MirY, RouxelCet al. Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: drug delivery, one and two-photon photodynamic therapy. Int. J. Pharm. 432 (1–2), 99–104 (2012).
  • Mamaeva V , RosenholmJM, Bate-EyaLTet al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol. Ther. 19(8), 1538–1546 (2011).
  • Mamaeva V , SahlgrenC, LindenM. Mesoporous silica nanoparticles in medicine – recent advances. Adv. Drug Del. Rev.65(5), 689–702 (2013).
  • Gary-Bobo M , MirY, RouxelCet al. Mannose-functionalized mesoporous silica nanoparticles for efficient two-photon photodynamic therapy of solid tumors. Angew Chem. Int. Ed. Engl. 50(48), 11425–11429 (2011).
  • Youns M , HoheiselJD, EfferthT. Therapeutic and diagnostic applications of nanoparticles. Curr. Drug Targets12(3), 357–365 (2011).
  • Rosenholm JM , MamaevaV, SahlgrenC, LindenM. Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage. Nanomed. (Lond.)7(1), 111–120 (2012).
  • Hebner C , WeaverVM, DebnathJ. Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures. Ann. Rev. Path.3, 313–339 (2008).
  • Friedrich J , EbnerR, Kunz-SchughartLA. Experimental anti-tumor therapy in 3-D: spheroids – old hat or new challenge? Int. J. Radiat. Biol.83(11–12), 849–871 (2007).
  • Bissell MJ , HinesWC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med.17(3), 320–329 (2011).
  • Nelson CM , BissellMJ. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol.22, 287–309 (2006).
  • Bissell MJ , LabargeMA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell7(1), 17–23 (2005).
  • Rosenholm JM , PeuhuE, ErikssonJE, SahlgrenC, LindenM. Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems. Nano Lett.9(9), 3308–3311 (2009).
  • Rosenholm JM , PeuhuE, Bate-EyaLT, ErikssonJE, SahlgrenC, LindenM. Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. Small6(11), 1234–1241 (2010).
  • Purow B . Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol.727, 305–319 (2012).
  • Li JL , JubbAM, HarrisAL. Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol.6(7), 1099–1103 (2010).
  • Yan M , CallahanCA, BeyerJCet al. Chronic DLL4 blockade induces vascular neoplasms. Nature 463(7282), e6–e7 (2010).
  • van Es JH , van Gijn ME, Riccio O et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature435(7044), 959–963 (2005).
  • Wong GT , ManfraD, PouletFMet al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279(13), 12876–12882 (2004).
  • Romberg B , HenninkWE, StormG. Sheddable coatings for long-circulating nanoparticles. Pharm. Res.25(1), 55–71 (2008).
  • Vargas A , Zeisser-LabouebeM, LangeN, GurnyR, DelieF. The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. Adv. Drug Del. Rev.59(11), 1162–1176 (2007).
  • Deryugina EI , QuigleyJP. Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem. Cell Biol.130(6), 1119–1130 (2008).
  • Kunzi-Rapp K , GenzeF, KuferR, ReichE, HautmannRE, GschwendJE. Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. J. Urology166(4), 1502–1507 (2001).
  • Ribatti D , NicoB, MangieriDet al.: In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. Histol. Histopathol.22(3), 285–289 (2007).
  • Vogler M , WalczakH, StadelDet al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 69(6), 2425–2434 (2009).
  • Vogler M , WalczakH, StadelDet al. Targeting XIAP bypasses BCL-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res. 68(19), 7956–7965 (2008).
  • Wittig-Blaich SM , KacprzykLA, EismannTet al. Matrix-dependent regulation of AKT in hepsin-overexpressing PC3 prostate cancer cells. Neoplasia 13(7), 579–589 (2011).
  • Rosenholm JM , MeinanderA, PeuhuEet al. Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano 3(1), 197–206 (2009).
  • Rosenholm JM , PenninkangasA, LindenM. Amino-functionalization of large-pore mesoscopically ordered silica by a one-step hyperbranching polymerization of a surface-grown polyethyleneimine. Chem. Commun. (Camb.)37, 3909–3911 (2006).
  • Rosenholm JM , LindenM. Wet-chemical analysis of surface concentration of accessible groups on different amino-functionalized mesoporous SBA-15 silicas. Chem. Mat.19(20), 5023–5034 (2007).
  • Schneckenburger H , WeberP, WagnerMet al. Light exposure and cell viability in fluorescence microscopy. J. Microscopy 245(3), 311–318 (2012).
  • Rizzo P , MiaoH, D‘SouzaGet al. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 68(13), 5226–5235 (2008).
  • Landor SK , MutveiAP, MamaevaVet al. Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms. Proc. Natl Acad. Sci. USA 108(46), 18814–18819 (2011).
  • Sahlgren C , GustafssonMV, JinS, PoellingerL, LendahlU. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Natl Acad. Sci. USA105(17), 6392–6397 (2008).
  • Stylianou S , ClarkeRB, BrennanK. Aberrant activation of Notch signaling in human breast cancer. Cancer Res.66(3), 1517–1525 (2006).
  • Hattori Y , MaitaniY. Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther.12(10), 796–809 (2005).
  • Bin Hafeez B , AdhamiVM Asim M et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin. Cancer Res.15(2), 452–459 (2009).
  • Zeisser-Labouebe M , DelieF, GurnyR, LangeN. Screening of nanoparticulate delivery systems for the photodetection of cancer in a simple and cost-effective model. Nanomed. (Lond.)4(2), 135–143 (2009).
  • Wang AZ , LangerR, FarokhzadOC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med.63, 185–198 (2012).
  • Mahmood M , CascianoD, XuY, BirisAS. Engineered nanostructural materials for application in cancer biology and medicine. J. Appl. Toxicol.32(1), 10–19 (2012).
  • Katsogiannou M , PengL, CatapanoCV, RocchiP. Active-targeted nanotherapy strategies for prostate cancer. Curr. Cancer Drug Targets11(8), 954–965 (2011).
  • von Maltzahn G , ParkJH, LinKYet al. Nanoparticles that communicate in vivo to amplify tumor targeting. Nat. Mater. 10(7), 545–552 (2011).
  • Ruoslahti E , BhatiaSN, SailorMJ. Targeting of drugs and nanoparticles to tumors. J. Cell Biol.188(6), 759–768 (2010).
  • Arap W , PasqualiniR, RuoslahtiE. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science279(5349), 377–380 (1998).
  • Olafsen T , GuZ, ShermanMAet al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J. Immunother. 30(4), 396–405 (2007).
  • Kelly KA , SetlurSR, RossRet al. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res. 68(7), 2286–2291 (2008).
  • Taylor RM , SevernsV, BrownDC, BisoffiM, SillerudLO. Prostate cancer targeting motifs: expression of alphanu beta3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. Prostate72(5), 523–532 (2012).
  • Denmeade SR , MhakaAM, RosenDMet al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci. Transl. Med. 4(140), 140ra86 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.